The Myeloproliferative Neoplasms Channel on VJHemOnc is an independent medical education platform, supported with funding from Takeda (Gold) and Kartos Therapeutics, Inc. (Bronze). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
MPN Workshop of the Carolinas 2024 | Ongoing and future trials in MPN-AP/BP
Anand Patel, MD, University of Chicago Medical Center, Chicago, IL, discusses ongoing and upcoming trials for patients with myeloproliferative neoplasms (MPNs) in the accelerated or blast-phase (MPN-AP/BP). Recent studies have explored the use of hypomethylating agents (HMAs) in combination with ruxolitinib, as well as targeted approaches using JAK and IDH2 inhibition. Dr Patel highlights how the results of these trials are encouraging but emphasizes the importance of preclinical research identifying new potential treatment targets. This interview took place at the 1st Annual MPN Workshop of the Carolinas in Asheville, NC.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
Disclosures
Honoraria:BMS, AbbVie, Sobi; Research funding (institutional): Pfizer, Sumitomo, Kronos Bio.
